Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Generalized Additive Models: An Introduction with R

Wood, S. N. (2017) · doi:10.1201/9781315370279 · Cited by 13,852

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897

Sensitivity analysis in observational research: Introducing the E-value

VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237

Cell entry mechanisms of SARS-CoV-2

Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., & Li, F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003138117 · Cited by 3,142

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109

The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine

Chen, X., Mohapatra, A., Nguyen, H. T. V., Schimanski, L. M., Tan, T. K., Rijal, P., Chen, C., Cheng, S., Lee, W.-H., Chou, Y., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012246 · Cited by 3

Association between antibody responses post-vaccination and severe COVID-19 outcomes in Scotland

Macdonald, C., Palmateer, N. E., McAuley, A., Lindsay, L., Hasan, T., Hameed, S. S., Hall, E., Jeffrey, K., Grange, Z., Gousias, P., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00898-w · Cited by 3

SARS-CoV-2 incidence, seroprevalence, and antibody dynamics in a rural, population-based cohort: March 2020–July 2022

Petrie, J. G., Pattinson, D., King, J. P., Neumann, G., Guan, L., Jester, P. J., Rolfes, M. A. R., Meece, J. K., Kieke, B. A., Belongia, E. A., et al. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae125 · Cited by 2

Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty

Niyomnaitham, S., Chokephaibulkit, K., Pheerapanyawaranun, C., Toh, Z. Q., Licciardi, P. V., Satayasanskul, A., Jansarikit, L., & Assantachai, P. (2024) · The journal of nutrition health & aging · doi:10.1016/j.jnha.2024.100315 · Cited by 3

Elucidating the Immune Response to SARS-CoV-2: Natural Infection versus Covaxin/Covishield Vaccination in a South Indian Population

Vanamudhu, A., Arumugam, R. D., Nancy, A., Selvaraj, N., Moideen, K., Hissar, S. S., Ranganathan, U. D., Bethunaickan, R., Babu, S., & Kumar, N. P. (2024) · Viruses · doi:10.3390/v16081178 · Cited by 3

Safety and immunogenicity of a SARS-CoV-2 mRNA vaccine (SYS6006) in minks, cats, blue foxes, and raccoon dogs

Huo, H., Wang, J., Li, C., Xiao, S., Wang, H., Ge, J., Zhong, G., Wen, Z., Wang, C., Lang, Q., et al. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1468775 · Cited by 4

Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial

Fong, Y., Dang, L., Zhang, B., Fintzi, J., Chen, S., Wang, J., Rouphael, N., Branche, A. R., Diemert, D. J., Falsey, A. R., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae465 · Cited by 3

Application of machine learning algorithms to identify serological predictors of COVID-19 severity and outcomes

Dhakal, S., Yin, A., Escarra‐Senmarti, M., Demko, Z. O., Pisanic, N., Johnston, T. S., Trejo‐Zambrano, M. I., Kruczynski, K. L., Lee, J. S., Hardick, J. P., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00658-w · Cited by 2

SECONDARY INFECTIONS IN THE FAMILY FROM PRIMARY CASES OF COVID-19 BREAKTHROUGH INFECTIONS IN FULLY VACCINATED OR NOT FULLY VACCINATED PEOPLE. TWO DOSES MODESTLY REDUCE FAMILY TRANSMISSION BUT DOES NOT ELIMINATE IT.

Turabián, J. L. (2022) · Journal of SARS-CoV-2 Research · doi:10.36013/sarc-cov-2.v2i.85 · Cited by 3

Evaluation of the Anti-Spike (RDB) IgG Titer among Workers Employed at the University of Pisa Vaccinated with Different Types of SARS-CoV-2 Vaccines

Foddis, R., Marino, R., Silvestri, R., Fallahi, P., Perretta, S., Garaffa, C., Morganti, R., Corsi, M., Mennucci, J., Porciatti, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10081244 · Cited by 3

Incidence of SARS‐CoV‐2 infection among unvaccinated US adults during the Omicron wave

Alejo, J. L., Chiang, T. P., Mitchell, J., Abedon, A. T., Jefferis, A. A., Werbel, W. A., Massie, A. B., Makary, M. A., & Segev, D. L. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13555 · Cited by 2

Patients with B-cell malignancies experience reduced antibody responses with class switching defect following BNT162b2 SARS-CoV-2 vaccination

Nakagama, Y., Chi, S., Minami, Y., Watanabe, R., Yamagishi, M., Atsuko, U., & Kido, Y. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.09.018 · Cited by 3

Dynamics of Anti-S IgG Antibodies Titers after the Second Dose of COVID-19 Vaccines in the Manual and Craft Worker Population of Qatar

Bansal, D., Atia, H., Badr, M. A., Nour, M., Abdulmajeed, J., Hasan, A., Al-Hajri, N., Ahmed, L., Ibrahim, R., Zamel, R., et al. (2023) · Vaccines · doi:10.3390/vaccines11030496 · Cited by 3

A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Potency and Non-Waning Humoral Response

Campbell, E., Dobkin, J., Osorio, L., Kolloli, A., Ramasamy, S., Kumar, R., Sant’Angelo, D. B., Subbian, S., Denzin, L. K., & Anderson, S. (2023) · Vaccines · doi:10.3390/vaccines11040832 · Cited by 3

VACCINES VERSUS COVID-19 VACCINES: MANEUVER TIMELINE OF DEVELOPMENT AND TRIAL DESIGNS

Gaddam, S., Pasupulati, H., & Padi, S. S. V. (2023) · World Journal of Current Medical and Pharmaceutical Research · doi:10.37022/wjcmpr.v5i3.265 · Cited by 4

Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals

Kuzel, T. G., Fu, J., Anderson, M., Stec, M., Boler, M., Behun, D., Gosha, A., Cloherty, G., LANDAY, A. L., & Moy, J. N. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.12.049 · Cited by 2

Assessment of Anti-SARS-CoV-2 antibody levels among university students vaccinated with different COVID-19 primary and booster doses — fall 2021, Wisconsin

DeJonge, P. M., Lambrou, A. S., Segaloff, H. E., Bateman, A., Sterkel, A., Griggs, C. B., Baggott, J., Kelly, P., Thornburg, N. J., Epperson, M., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08332-7 · Cited by 3

Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role?

Broccolo, F. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-1345 · Cited by 4

Immune response to 2-dose BNT162b2 vaccination and risk of SARS-CoV-2 breakthrough infection: The Shieldvacc-2 studyPreprint

Seekircher, L., Bánki, Z., Kimpel, J., Rössler, A., Schäfer, H., Falkensammer, B., Bante, D., Forer, L., Schönherr, S., Harthaller, T., et al. (2022) · medRxiv · doi:10.1101/2022.04.19.22273872 · Cited by 3

Humoral Responses in the Omicron Era following Three-Dose SARS-CoV-2 Vaccine Series in Kidney Transplant RecipientsPreprint

McEvoy, C. M., Hu, Q., Abe, K. T., Yau, K., Oliver, M. J., Levin, A., Gingras, A., Hladunewich, M., & Yuen, D. A. (2022) · medRxiv · doi:10.1101/2022.06.24.22276144 · Cited by 3

Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workersPreprint

Nugent, C., Abul, Y., White, E. M., Shehadeh, F., Kaczynski, M., Felix, L. O., Ganesan, N., Oyebanji, O. A., Vishnepolskiy, I., Didion, E. M., et al. (2023) · medRxiv · doi:10.1101/2023.01.22.23284881 · Cited by 3

CD4+ and CD8+ T cell and antibody correlates of protection against Delta vaccine breakthrough infection: A nested case-control study within the PITCH studyPreprint

Neale, I., Ali, M., Kronsteiner, B., Longet, S., Abraham, P., Deeks, A. S., Brown, A., Moore, S. C., Stafford, L., Dobson, S. L., et al. (2023) · medRxiv · doi:10.1101/2023.02.16.23285748 · Cited by 3

Early antiviral CD4 and CD8 T cell responses and antibodies are associated with upper respiratory tract clearance of SARS-CoV-2Preprint

Ramirez, S. I., Lopez, P. G., Faraji, F., Parikh, U. M., Heaps, A., Ritz, J., Moser, C., Eron, J. J., Wohl, D. A., Currier, J. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.25.564014 · Cited by 3

Submicro-Optical Spectroscopy Bioassay System for COVID-19 Neutralizing Antibody Immunity Response

Tsai, C.-M., Chiu, W.-H., Kong, W.-Y., Hong, C., Ko, C., & Fang, W. (2024) · IEEE Sensors Journal · doi:10.1109/jsen.2024.3424557 · Cited by 2

Modelling the Relative Vaccine Efficacy of ARCT-154, a Self-Amplifying mRNA COVID-19 Vaccine, versus BNT162b2 Using Immunogenicity Data

Nguyen, V. H., Crépey, P., Pivette, J. M., Settembre, E., Rajaram, S., Youhanna, J., Ferraro, A., Chang, C., van Boxmeer, J., & Mould-Quevedo, J. F. (2024) · Vaccines · doi:10.3390/vaccines12101161 · Cited by 2

Designs for Vaccine Studies

Halloran, M. E. (2024) · Annual Review of Statistics and Its Application · doi:10.1146/annurev-statistics-033121-120121 · Cited by 2

Enhancing Immune Responses Through Modulation of Innate Cell Microenvironments in Lymph Nodes with Virus‐Mimetic Vaccines

Su, R., Yao, T., Cao, C., Yang, Y., Chen, M., Wu, J., Zhao, Y., Liu, X., Li, S., Ding, J., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202503845 · Cited by 3

The Impact of Vaccination Frequency on COVID-19 Public Health Outcomes: A Model-Based Analysis

Stoddard, M., Yuan, L., Sarkar, S., Egeren, D. V., Mangalaganesh, S., Nolan, R. P., Rogers, M. S., Hather, G., White, L. F., & Chakravarty, A. (2025) · Vaccines · doi:10.3390/vaccines13040368 · Cited by 8

SARS-CoV-2 vaccines elicit differential Fc effector functions

Manamela, N. P., Motsoeneng, B. M., Spencer, H., Hermanus, T., Mzindle, N. B., Ayres, F., Makhado, Z., Serage, R., Gray, G., Bekker, L., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113084 · Cited by 4

Impact of vaccination behavior on COVID-19 dynamics and economic outcomes

Alsammani, A., Ngonghala, C. N., & Martcheva, M. (2025) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2025084 · Cited by 6

A biomimetic model composed of injectable 3D muscle-like tissue, stromal and immune cells for recapitulating the rapid immune signature predictive of mRNA vaccine immunogenicity

Etna, M. P., Fuoco, C., Severa, M., Ricci, D., Sinigaglia, A., Lucca, C., Cairo, G., Bottazzi, B., Garlanda, C., Palamara, A. T., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1651095 · Cited by 3

Clinical Pharmacology Approaches to Predict Efficacy of Monoclonal Antibodies Against Emerging SARS ‐ CoV ‐2 Variants

Wang, Q., Nader, A., Peppercorn, A., Skingsley, A., Lloyd, E. J., Stella, A. O., Walker, J., & Garner, C. (2025) · Clinical and Translational Science · doi:10.1111/cts.70421 · Cited by 2

Two-year persistence of MERS-CoV-specific antibody and T cell responses after MVA-MERS-S vaccination in healthy adults

Mayer, L., Fathi, A., Weichel, H.-M., Raadsen, M. P., Dahlke, C., Mykytyn, A. Z., Rodon, J., Gerresheim, G. K., Marvelde, M. R. T., Weskamm, L. M., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68248-5 · Cited by 2

Possible role of pre-vaccination T-lymphocyte subpopulations in the antibody response to COVID-19 vaccines in children undergoing chemotherapy

Péterfia, C., Komlósi, Z. I., Pós, Z., Lupsa, N., Fekete, N., Böröcz, K., Dergez, T., Leibinger, E. A., Benedek, N., Vojcek, Á., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1728845 · Cited by 2

Potent and dose-sparing next-generation SARS-CoV-2 vaccine, mRNA-1283, induces polyfunctional and durable T cell immunity

Paila, Y. D., Pajón, R., Banbury, B. L., Fields, P., Maglinao, M., Rosa, S. C. D., Morris, D. E., McElrath, M. J., Siangphoe, U., Cohen, K. W., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01402-2 · Cited by 2

The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults

Whitaker, J. A., Rebolledo, P. A., Abate, G., Babu, T. M., Rouphael, N. G., Wald, A. P., Sahly, H. M. E., Jooss, K. U., Hart, M. G., Makowski, M., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128358 · Cited by 2

iGraphCTC: an inter-connected graph convolutional network for comprehensive clinical trial collaborations

Jang, J., Ahn, H., & Park, E. K. (2026) · Scientific Reports · doi:10.1038/s41598-026-40836-5 · Cited by 2

Immune responses associated with protection from SARS-CoV-2 infection

Reynaldi, A., Lee, W. S., Selva, K. J., Audsley, J., Trieu, M.-C., Chung, A. W., Cromer, D., Tan, H., Wheatley, A. K., Juno, J. A., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128579 · Cited by 2

Cross-direct effects in settings with two mediators

Gabriel, E. E., Sjölander, A., Follmann, D. A., & Sachs, M. C. (2022) · Biostatistics · doi:10.1093/biostatistics/kxac037 · Cited by 2

Maternal–foetal transfer of severe acute respiratory syndrome coronavirus 2 antibodies among women with and those without HIV infection

Nunes, M. C., Jones, S., Ditse, Z., da Silva, K., Serafin, N., Strehlau, R., Wise, A. J., Burke, M., Baba, V., Baillie, V. L., et al. (2022) · AIDS · doi:10.1097/qad.0000000000003345 · Cited by 2

Multiparametric Prediction Models for Coronavirus Disease 2019 Vaccine Selection: Results of a Comparative Population-Based Cohort Study

Sieghart, D., Hana, C. A., Haslacher, H., Perkmann, T., Heinz, L. X., Fedrizzi, C., Anderle, K., Wiedermann, U., Condur, I., Drapalik, S., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac840 · Cited by 2

Understanding and Improving Vaccine Effectiveness Estimates in the Age of Widespread Background Immunity: A Step Toward Improved Science Communication

Nirenberg, E., & Perencevich, E. N. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad124 · Cited by 2

Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults

Wu, Y., Huang, P., Xu, M., Zhao, Q., Xu, Y., Han, S., Li, H., & Wang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152899 · Cited by 3

Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell transplant recipients: A Japanese multicenter observational study

Mori, Y., Uchida, N., Wake, A., Miyawaki, K., Eto, T., Nakamura, T., Iwasaki, H., Ito, Y., Tanimoto, K., Katayama, Y., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.08.066 · Cited by 2

Innate and Adaptive Cell-Mediated Immune Responses to a COVID-19 mRNA Vaccine in Young Children

Weinberg, A., Johnson, M. J., Garth, K. M., Hsieh, E. W. Y., Kedl, R. M., Weiskopf, D., Cassaday, M., Rester, C., Cabrera-Martinez, B., Baxter, R. M., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad608 · Cited by 2

HLA-DQ Diversity Is Associated With Humoral Response to Vaccines in Patients Awaiting or After Liver Transplantation

Féray, C., Allain, V., Desterke, C., Roche, B., Coilly, A., & Caillat‐Zucman, S. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.009 · Cited by 2

SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost

Lijeskić, O., Bauman, N., Marković, M., Srbljanović, J., Bobić, B., Zlatković, Đ., & Štajner, T. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.085 · Cited by 2

Omicron BA.4/5 neutralization and cell‐mediated immune responses in relation to baseline immune status and breakthrough infection among PLWH: A follow‐up cohort study

Zhan, H., Xie, Y., Liu, Y., Cheng, L., Xu, Y., Qu, X., Li, C., Guo, X., Li, H., Wang, Y., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29446 · Cited by 2

How to Accelerate Early Stage of Malaria Vaccine Development by Optimizing Functional Assays

Miura, K. (2024) · Vaccines · doi:10.3390/vaccines12060586 · Cited by 2

Antibody Response to Symptomatic Infection With SARS‐CoV‐2 Omicron Variant Viruses, December 2021–June 2022

Sandford, R., Yadav, R., Noble, E. K., Sumner, K. M., Joshi, D., Tartof, S. Y., Wernli, K. J., Martin, E. T., Gaglani, M., Zimmerman, R. K., et al. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13339 · Cited by 2

Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an Omicron surge in Japan

Matsumoto, N., Sasaki, A., Kadowaki, T., Mitsuhashi, T., Takao, S., & Yorifuji, T. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126156 · Cited by 3

Causal Mediation Analyses for the Natural Course of Hepatitis C: A Prospective Cohort Study

Huang, Y.-T., Hsu, Y., Yang, H., Lee, M., Lai, T.-H., Chen, C., & Huang, Y. (2024) · Journal of Epidemiology · doi:10.2188/jea.je20240034 · Cited by 2

Prevalence and risk factors of post-acute sequelae of SARS-CoV-2 (PASC) among veterans in the airborne hazards and open burn pit registry: a prospective, observational, nested study

Phen, S. M., Jani, N., Klein‐Adams, J. C., Ndirangu, D. S., Rahman, A., & Falvo, M. J. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09730-1 · Cited by 2

Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants

Chalouni, M., Loubet, P., Lhomme, E., Ninove, L., Barrou, B., Blay, J., Hourmant, M., Seze, J. D., Laville, M., Laviolle, B., et al. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09861-5 · Cited by 2

Assessment of neutralizing antibody response as a correlate of protection against symptomatic SARS-CoV-2 infections after administration of two doses of the CoronaVac inactivated COVID-19 vaccine: A phase III randomized controlled trial

Chen, X., Meng, X., Wu, Q., Lim, W. W., Xin, Q., Cowling, B. J., Meng, W., Yu, H., & Covas, D. T. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106315 · Cited by 3

STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease

Woelfel, S., Junker, D., Bergamin, I., Meyer-Herbon, P., Stillhard, R., Graf, N., Leinenkugel, G., Dütschler, J., König, M., Kammerlander, L., et al. (2024) · Vaccines · doi:10.3390/vaccines12111241 · Cited by 2

A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy of anti-receptor binding domain antibodies elicited by SARS-CoV-2 hybrid immunity

Ana‐Sosa‐Batiz, F., Verma, S. K., Shafee, N., Miller, R., Conner, C., Hastie, K. M., Timis, J., Maule, E., Nguyen, M. N., Tran, L., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105619 · Cited by 2

Evaluation of humoral and cellular immune responses in healthcare workers with varying levels of SARS-CoV-2 exposure: effects of CoronaVac vaccination followed by heterologous booster

Gomes, S. M. R., Alves, M. R., Ribeiro, R. S. D. A., Brito, A. C. D. S., Lisboa, V. D. C., de Azevedo, S. G., Nogueira, J. D. S., Castilho, L. R., Pôrto, L. C., Da-Silva, S. A. G., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1576430 · Cited by 2

Development and Validation of Novel Cell‐free Direct Neutralization Assay for SARS-CoV-2

Lim, J. Y., Fiore, A., Le, B., Minzer, C., White, H., Burinski, K., Janwari, H., Wright, D. J., Perebikovsky, S., Davis, R., et al. (2025) · Journal of Virological Methods · doi:10.1016/j.jviromet.2025.115201 · Cited by 2

COVID-19 mRNA or viral vector vaccine type and subject sex influence the SARS-CoV-2 T-cell response

Tong, S., Litwin, S. M., Epel, E. S., Lin, J., Drury, S. S., Hecht, F. M., Robinson, J. E., Prather, A. A., & Norton, E. B. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127420 · Cited by 2

Exploring the Immune Response to COVID ‐19 Vaccines in Dialysis and Transplant Patients

You, H. W., Lim, S. K., Kong, B. H., Cheng, S. F., Rajasuriar, R., & You, H. W. (2025) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.70066 · Cited by 2

Semiparametric efficient estimation of small genetic effects in large-scale population cohorts

Labayle, O., Roskams-Hieter, B., Slaughter, J., Tetley-Campbell, K., van der Laan, M. J., Ponting, C. P., Beentjes, S. V., & Khamseh, A. (2024) · Biostatistics · doi:10.1093/biostatistics/kxaf030 · Cited by 4

Nomogram Model for Prediction of SARS-CoV-2 Breakthrough Infection in Fujian: A Case–Control Real-World Study

Chen, T., Zeng, Y., Yang, D., Ye, W., Zhang, J., Lin, C., Huang, Y., Ye, Y., Li, J., Ou, Q., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.932204 · Cited by 2

The Effects of an mRNA Covid-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans

Frankel, A. E., Capozzola, T., Andrabi, R., Ahn, C. W., Zhou, P.-P., He, W., & Burton, D. R. (2022) · Medical Research Archives · doi:10.18103/mra.v10i7.2932 · Cited by 2

Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants

Tuffy, K. M., Ahani, B., Aksyuk, A. A., Avila, M., Brady, T. M., Kijak, G. H., Koh, G. C. K. W., Levin, M. J., Roe, T. L., Schuko, N., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad210 · Cited by 2

Placebo control group in COVID-19 vaccine trials: context and timing matters

Dal‐Ré, R. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03259-x · Cited by 3

Harmonization of Determination of SARS-CoV-2 Antibodies: Is It Always Possible?

Dittadi, R. (2022) · Diagnostics · doi:10.3390/diagnostics12020483 · Cited by 2

Enhanced immunity after Ad26.COV2.S vaccine breakthrough infection

Montefiori, D. C. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100579 · Cited by 2

Vaccination of cats with Sad23L-nCoV-S vaccine candidate against major variants of SARS-CoV-2

Zhang, P., Luo, S., Zou, P., Liang, C., Wang, C., Li, J., Li, Y., Wang, G., Zhang, L., Li, T., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.06.011 · Cited by 2

Comparing and combining data from immune assays based on left‐censored multivariate normal model assuming common assay differences across settings

Huang, Y., & Huang, Y. (2022) · Statistics in Medicine · doi:10.1002/sim.9607 · Cited by 2

Kinetics of Neutralizing Antibodies against Omicron Variant in Vietnamese Healthcare Workers after Primary Immunization with ChAdOx1-S and Booster Immunization with BNT162b2

Chau, N. V. V., Nguyet, L. A., Dung, N. T., Quang, V. M., Truong, N. T., Toan, L. M., Hung, L. M., Man, D. N. H., Khoa, D. B., Phong, N. T., et al. (2022) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.22-0434 · Cited by 2

The Best and Sustainable COVID-19 Policy in the World

Takefuji, Y. (2022) · IEEE Transactions on Computational Social Systems · doi:10.1109/tcss.2022.3227926 · Cited by 2

Exploring the Potential of Broadly Neutralizing Antibodies for Treating SARS-CoV-2 Variants of Global Concern in 2023: A Comprehensive Clinical Review

Gutlapalli, S. D., Ganipineni, V. D. P., Danda, S., Fabián, D., Okorie, I. J., Paramsothy, J., Kailayanathan, T., Umyarova, R., Aviles, C., Garlapati, S. K. P., et al. (2023) · Cureus · doi:10.7759/cureus.36809 · Cited by 2

Longitudinal Neutralizing and Functional Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants Following Messenger RNA Coronavirus Disease 2019 Vaccination

Chen, X., Ciric, C. R., Gibson, T., Anderson, L. J., Anderson, E. J., & Rostad, C. A. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad167 · Cited by 2

SARS-CoV-2 RBD Conjugated to Polyglucin, Spermidine, and dsRNA Elicits a Strong Immune Response in Mice

Volosnikova, E. A., Merkuleva, I. A., Esina, T. I., Щербаков, Д. Н., Borgoyakova, M. B., Исаева, А. А., Nesmeyanova, V. S., Волкова, Н. В., Belenkaya, S. V., Zaykovskaya, A. V., et al. (2023) · Vaccines · doi:10.3390/vaccines11040808 · Cited by 2

Anti-SARS-CoV-2 antibody among SARS-CoV-2 vaccinated vs post-infected blood donors in a tertiary hospital, Bangkok, Thailand

Permpikul, P., Tongyoo, S., Chaimayo, C., Kanpai, P., Virat, J., Virat, S., Chuchaaim, J., Thongput, A., & Bhatnagar, S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285737 · Cited by 3

Simultaneous Quantitative SARS-CoV-2 Antigen and Host Antibody Detection and Pre-Screening Strategy at the Point of Care

Rajsri, K. S., McRae, M. P., Christodoulides, N. J., Dapkins, I. P., Simmons, G. W., Matz, H. C., Dooley, H. M., Fenyö, D., & McDevitt, J. T. (2023) · Bioengineering · doi:10.3390/bioengineering10060670 · Cited by 2

Retained avidity despite reduced cross-binding and cross-neutralizing antibody levels to Omicron after SARS-COV-2 wild-type infection or mRNA double vaccination

Harthaller, T., Falkensammer, B., Bante, D., Huber, M., Schmitt, M. M., Benainouna, H. B., Rössler, A., Fleischer, V., von Laer, D., Kimpel, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1196988 · Cited by 3

Comparison of SARS-CoV-2 Hyperimmune Immunoglobulins Following Infection Plus Vaccination vs Infection

Bellusci, L., Golding, H., & Khurana, S. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.27307 · Cited by 2

Comparison of Antibody Responses After CoronaVac and BNT162b2 Vaccines in Healthcare Workers

GÜLTEKİN, E. O., & GÜLTEKİN, O. (2023) · Indian Journal of Microbiology · doi:10.1007/s12088-023-01098-1 · Cited by 2

SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients

Geinitz, H., Silberberger, E., Spiegl, K. J., Feichtinger, J., Wagner, H., Hermann, P., Bräutigam, E., Track, C., Weis, E. M., Venhoda, C., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.006 · Cited by 2

The roles of CD4+ T cell help, sex, and dose in the induction of protective CD8+ T cells against a lethal poxvirus by mRNA-LNP vaccines

Kafle, S., Montoya, B., Tang, L., Tam, Y. K., Muramatsu, H., Pardi, N., & Sigal, L. J. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102279 · Cited by 2

Broad and Long-lasting Immune Response against SARS-CoV-2 Omicron and Other Variants by PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine (YS-SC2-010)Preprint

Liu, Y., Zhang, N., Wang, B., & Zhang, Y. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.22.473615 · Cited by 2

Predicted Symptomatic Effectiveness of Pfizer-BioNTech BNT162b2 Vaccine Against Omicron Variant of SARS-CoV-2Preprint

Volkov, O. (2021) · medRxiv · doi:10.1101/2021.12.09.21267556 · Cited by 2

Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE TrialPreprint

Sahly, H. M. E., Baden, L. R., Essink, B. J., Montefiori, D. C., McDermont, A., Rupp, R. E., Lewis, M., Swaminathan, S., Griffin, C., Fragoso, V. G., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3988003 · Cited by 2

The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNA vaccinesPreprint

Carreño, J. M., Raskin, A. J., Singh, G., Tcheou, J., Kawabata, H., Gleason, C., Srivastava, K., Vigdorovich, V. I., Dambrauskas, N., Gupta, S. L., et al. (2022) · medRxiv · doi:10.1101/2022.01.25.22269808 · Cited by 2

Variation of total anti-SARS-CoV-2 antibodies after primary BNT162b2 vaccination and homologous boosterPreprint

Salvagno, G. L., Henry, B. M., Pighi, L., NITTO, S. D., & Lippi, G. (2022) · Research Square · doi:10.21203/rs.3.rs-1476525/v1 · Cited by 2

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim AnalysisPreprint

Anderson, E. J., Jackson, L. A., Rouphael, N., Widge, A. T., Montefiori, D. C., Doria‐Rose, N. A., Suthar, M. S., Cohen, K. W., O’Connell, S. E., Makowski, M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1222037/v1 · Cited by 2

Selection of Optimum Formulation of RBD-Based Protein Sub-Unit COVID19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical StudiesPreprint

Thuluva, S., Paradkar, V. M., Turaga, K., Gunneri, S., Yerroju, V., Mogulla, R. R., Kyasani, M., Manoharan, S., Medigeshi, G. R., Singh, J., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4055319 · Cited by 2

Humoral Immunity to SARS-CoV-2 and Inferred Protection from Infection in a French Longitudinal Community CohortPreprint

Woudenberg, T., Pinaud, L., García, L., Tondeur, L., Pelleau, S., Thoisy, A. D., Donnadieu, F., Backović, M., Attia, M., Hozé, N., et al. (2022) · medRxiv · doi:10.1101/2022.05.23.22275460 · Cited by 2

An Evaluation of the Safety and Immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled studyPreprint

Torales, J. C., Cuenca-Torres, O., Barrios, L., Armoa, L., Estigarribia, G., Sanabria, G., Lin, M., Estrada, J. A. G., Estephan, L., Cheng, H., et al. (2022) · medRxiv · doi:10.1101/2022.07.14.22277617 · Cited by 2

Correlates of protection for booster doses of the BNT162b2 vaccinePreprint

Hertz, T., Levy, S., Ostrovsky, D. A., Oppenheimer, H., Zismanov, S., Kuzmina, A., Friedman, L. M., Trifkovic, S., Brice, D. C., Chun-Yang, L., et al. (2022) · medRxiv · doi:10.1101/2022.07.16.22277626 · Cited by 2

Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic FibrosisPreprint

Alicandro, G., Daccò, V., Cariani, L., Rosazza, C., Sciarrabba, C. S., Ferraro, F., Lanfranchi, C., Medino, P., Girelli, D., & Colombo, C. (2022) · Preprints.org · doi:10.20944/preprints202207.0422.v1 · Cited by 2

A Long Interval Between Priming and Boosting SARS-CoV-2 mRNA Vaccine Doses Enhances B Cell Responses With Limited Impact on T Cell ImmunityPreprint

Nicolas, A., Sannier, G., Dubé, M., Nayrac, M., Painter, M. M., Goel, R. R., Laporte, M., Medjahed, H., Williams, J. C., Brassard, N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.03.502672 · Cited by 2

A replicon RNA vaccine induces durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have wanedPreprint

O’Connor, M. A., Hawman, D. W., Meade-White, K. D., Leventhal, S. S., Song, W., Randall, S., Archer, J. F., Lewis, T. B., Brown, B., Iwayama, N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.08.503239 · Cited by 2

Dose of approved COVID-19 vaccines is based on weak evidence: a review of early-phase, dose-finding trialsPreprint

Dunn, D. T., Gilson, R. J. C., McCormack, S., & McCoy, L. E. (2022) · medRxiv · doi:10.1101/2022.09.20.22276701 · Cited by 2

A randomized, placebo-controlled trial of a nasal spray solution containing broadly potent neutralizing antibodies against SARS-CoV-2 variants in healthy volunteersPreprint

Imsuwansri, T., Jongthitinon, T., Pojdoung, N., Meesiripan, N., Sakarin, S., Boonkrai, C., Wongtangprasert, T., Phakham, T., Audomsun, T., Attakitbancha, C., et al. (2022) · medRxiv · doi:10.1101/2022.10.04.22280574 · Cited by 2

A Phase II Study Integrating a Single-Blind Safety Phase with a Double-Blind, Placebo-Controlled Randomized Phase, Assessing Single-Dose Intramuscular or Intranasal Administration to Evaluate the Safety and Immunogenicity of the Recombinant Vaccine Against COVID-19 (AVX/COVID-12 “Patria”) Based on an Active Newcastle Disease Viral Vector as a Heterologous Booster in Subjects with Evidence of Previous Immunity to SARS-CoV-2Preprint

López-Macías, C. I. R., Torres, M., Armenta-Copca, B., Wacher, N. H., Castro-Castrezana, L., Colli-Domínguez, A. A., Rivera-Hernández, T., Torres-Flores, A., Ramírez-Martínez, L. A., la Rosa, G. P.-D., et al. (2024) · medRxiv · doi:10.1101/2024.02.11.24302594 · Cited by 2

Use of the test-negative design to estimate the protective effect of a scalar immune measure: A simulation analysisPreprint

Zhang, Z., Boyer, C., & Lipsitch, M. (2024) · medRxiv · doi:10.1101/2024.11.22.24317757 · Cited by 2

Predicting age-related determinants of heterogeneous outcomes to COVID-19 mRNA vaccines through mathematical modellingPreprint

Deng, X., Farhang‐Sardroodi, S., & Craig, M. (2025) · medRxiv · doi:10.1101/2025.02.14.25322308 · Cited by 3

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial

Benkeser, D. C., Montefiori, D. C., McDermott, A. B., Fong, Y., Janes, H., Deng, W., Zhou, H., Houchens, C. R., Martins, K. A. O., Jayashankar, L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade9078 · Cited by 44

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Fong, Y., Huang, Y., Benkeser, D. C., Carpp, L. N., Áñez, G., Woo, W., McGarry, A., Dunkle, L. M., Cho, I., Houchens, C. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35768-3 · Cited by 101

Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial

Huang, Y., Hejazi, N. S., Blette, B. S., Carpp, L. N., Benkeser, D. C., Montefiori, D. C., McDermott, A. B., Fong, Y., Janes, H., Deng, W., et al. (2023) · Viruses · doi:10.3390/v15102029 · Cited by 15

Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE TrialPreprint

Sahly, H. M. E., Baden, L. R., Essink, B. J., Montefiori, D. C., McDermont, A., Rupp, R. E., Lewis, M., Swaminathan, S., Griffin, C., Fragoso, V. G., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3988003 · Cited by 2

Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine

Ma, C., Feng, J., Wahid, R., Chalkias, S., Edwards, D., Girard, B., Das, R., Zhou, H., & Zheng, L. (2026) · Figshare · doi:10.6084/m9.figshare.32531162